CORE
🇺🇦Â
 make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
2 research outputs found
HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials.
Author
Aleix Prat
Andres Forero-Torres
+18Â more
Anne Clarisse Pavlick
Antonio C. Wolff
Antonio Llombart-Cussac
Begona Bermejo
Brent Neil Rexer
C. Kent Osborne
Carmine De Angelis
Carolina Gutierrez
Ian E. Krop
Jamunarani Veeraraghavan
Javier Cortes
Mafalda Oliveira
Mothaffar F. Rimawi
Rachel Schiff
Serafin Morales
Susan G. Hilsenbeck
Tao Wang
Tomás Pascual
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref
A phase Ib study of abemaciclib with therapies for metastatic breast cancer.
Author
Alison Katherine Conlin
Brent Neil Rexer
+18Â more
Carlos Becerra
Donald A. Richards
Edward Michael Chan
Elizabeth Claire Dees
Howard A. Burris
J. Thaddeus Beck
Kevin Kalinsky
Matthew P. Goetz
Maura N. Dickler
Muralidhar Beeram
Na Cai
P. Kellie Turner
Paul R. Conkling
Sara M. Tolaney
Shannon Puhalla
Shubham Pant
Teresa L. Helsten
William Jeffery Edenfield
Publication venue
'American Society of Clinical Oncology (ASCO)'
Publication date
Field of study
No full text
Crossref